Skip to main content

Client News

FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region

11th March 2024

MIG Capital: MIG Capital leads €5 million Series A financing of animal healthcare company HawkCell to democratise MRI imaging

11th March 2024

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024isease transgenic model to be presented at AD/PD™ 2024 Conference

8th March 2024

Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023

6th March 2024

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

5th March 2024

CARBIOS Active, the enzymatic solution for 100% compostable PLA, added to FDA Inventory of Food Contact Substances

5th March 2024

Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve

29th February 2024

AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board

29th February 2024

CARBIOS and Landbell Group join forces to increase circularity of PET waste at first biorecycling plant

29th February 2024

Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer’s disease transgenic model to be presented at AD/PD™ 2024 Conference

28th February 2024